Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Form 4 for Quanterix Corp (QTRX) shows Toloue Masoud, President & CEO and a director, reported transactions dated 08/31/2025. The filing records a disposition of 254 shares of common stock at $4.55 per share. The disposition reflects shares withheld by the company to cover tax obligations upon the vesting of 761 restricted stock units (RSUs). After the reported transaction, Masoud beneficially owns 514,434 shares, which include 228,052 RSUs. The form was signed by an attorney-in-fact on 09/03/2025.
Quanterix Corporation (QTRX) will hold a virtual 2025 Annual Meeting at 9:00 a.m. ET on September 23, 2025, with a record date of July 31, 2025 and 46,465,915 shares outstanding. The Proxy Statement asks stockholders to vote on six proposals: election of three directors (Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David Walt, Ph.D.), an advisory vote on executive compensation, ratification of KPMG LLP as independent auditors for 2025, and three Charter amendments to declassify the Board and remove supermajority vote requirements for certain Charter and Bylaw amendments. The filing discloses the closing of the Akoya Biosciences acquisition on July 8, 2025 and related board changes with appointments of former Akoya directors. The Company entered a Cooperation Agreement with Kent Lake Partners on August 4, 2025, including commitments to appoint a new independent director by December 1, 2025 and to seek Board declassification. Voting procedures, quorum, and broker voting limitations are described for each proposal.
Sriram Vandana, Chief Financial Officer and reporting person for Quanterix Corporation (QTRX), reported a change in beneficial ownership on 08/15/2025. The filing shows a disposition of 229 shares of Quanterix common stock at a price of $4.57. The filing explains those shares were withheld by Quanterix solely to cover tax obligations upon the vesting of 777 restricted stock units (RSUs). After the reported transaction, Vandana beneficially owns 83,050 shares, which the filing notes includes 72,447 restricted stock units. The form is signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Toloue Masoud, President & CEO and director of Quanterix Corporation (QTRX), reported a transaction dated 08/15/2025 showing a disposition of 1,242 shares of common stock at a price of $4.57 per share under transaction code F. The filing explains those shares were withheld by the company to cover tax obligations related to the vesting of 3,722 restricted stock units (RSUs). After the reported transaction, the reporting person beneficially owns 514,688 shares, which the filing notes includes 228,813 restricted stock units. The form was signed by an attorney-in-fact on 08/19/2025.
Portolan Capital Management, LLC and its manager George McCabe report beneficial ownership of 3,633,622 shares of Quanterix Corp common stock, representing 9.36% of the class, as disclosed on a Schedule 13G (Amendment No. 3). The filing shows sole voting and sole dispositive power over these shares and indicates Portolan acts in its capacity as a registered investment adviser while Mr. McCabe is identified as the manager with indirect interest.
The statement includes a certification that the securities were not acquired to change or influence control of the issuer, consistent with a passive 13G filing. No shared voting or dispositive powers are reported and no other holders are identified in this filing.
Quanterix Corporation is asking stockholders to vote at a virtual annual meeting at 9:00 a.m. ET on September 23, 2025. Holders of record as of July 31, 2025 may vote on six proposals, including the election of three directors (Myla Lai-Goldman, Masoud Toloue and David Walt), an advisory say-on-pay vote, ratification of KPMG LLP as auditor, and three Charter amendments to declassify the Board and remove supermajority vote requirements for certain Charter and Bylaws amendments.
The company completed the acquisition of Akoya Biosciences on July 8, 2025, which led to two Akoya directors joining Quanterix and two predecessors resigning. A Cooperation Agreement with activist holder Kent Lake was reached on August 4, 2025, which includes appointing one independent director by December 1, 2025 and seeking Board declassification. The Board recommends voting in favor of all proposals.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
